Compare DRUG & OMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DRUG | OMDA |
|---|---|---|
| Founded | 2019 | 2011 |
| Country | United States | United States |
| Employees | N/A | 868 |
| Industry | Pharmaceuticals and Biotechnology | Medical/Nursing Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 707.1M | 711.1M |
| IPO Year | 2020 | N/A |
| Metric | DRUG | OMDA |
|---|---|---|
| Price | $71.35 | $13.51 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 10 |
| Target Price | ★ $124.00 | $24.00 |
| AVG Volume (30 Days) | 86.7K | ★ 1.5M |
| Earning Date | 05-15-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $22.07 |
| Revenue Next Year | N/A | $19.75 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $23.18 | $10.28 |
| 52 Week High | $123.75 | $26.92 |
| Indicator | DRUG | OMDA |
|---|---|---|
| Relative Strength Index (RSI) | 39.23 | 46.37 |
| Support Level | $71.04 | $10.28 |
| Resistance Level | $84.29 | $16.93 |
| Average True Range (ATR) | 3.99 | 0.79 |
| MACD | -0.82 | 0.06 |
| Stochastic Oscillator | 14.20 | 36.30 |
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
Omada Health Inc empowers individuals to make lasting health changes through personalized, virtual care between doctor's visits. The integrated platform of the company supports members with cardiometabolic conditions like prediabetes, diabetes, hypertension, musculoskeletal issues, and behavioral health needs. The company's specialized care tracks also assist members using GLP-1 medications. The Company delivers measurable health outcomes and value for employers, health plans, health systems, and pharmacy benefit managers.